Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Polycystic Ovary Syndrome 7Neoplasms 6Breast Neoplasms 6Vomiting 2Solid Tumors 2Skin Neoplasms 2Neoplasm Metastasis 2Melanoma 2Diabetes Mellitus 2Weight Gain 1Venous Thromboembolism 1Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Thrombocythemia, Essential 1Stem Cell Transplant Complications 1Skin Toxicity 1Renal Insufficiency 1Prostatic Neoplasms 1Primary Myelofibrosis 1Premature Birth 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pre-Eclampsia 1Polycythemia Vera 1Parathyroid Neoplasms 1Pain, Postoperative 1Ovarian Neoplasms 1Nausea 1Myeloproliferative Disorders 1Multiple Myeloma 1

Interventions

Dexamethasone 362Bortezomib 231Lenalidomide 200Cyclophosphamide 174Melphalan 154Calcium Dobesilate 107Peripheral Blood Stem Cell Transplantation 92fludarabine phosphate 84Thalidomide 81Filgrastim 71carfilzomib 68pomalidomide 66Granulocyte Colony-Stimulating Factor 60Mycophenolic Acid 59Busulfan 57daratumumab 54Whole-Body Irradiation 54Tacrolimus 51ixazomib 50Prednisone 50Cyclosporine 49fludarabine 46Antilymphocyte Serum 35Etoposide 30dexamethasone acetate 29Methotrexate 29plerixafor 27Radiotherapy 26Doxorubicin 26dexamethasone 21-phosphate 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Multiple Myeloma × Tablets × Clear all
NCT02045017 2021-08-27

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Celgene

Phase 2 Completed
81 enrolled
Plasma cell

Multiple Myeloma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡